Back Back
ASCO 2023: Hematologic Malignancies

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™

Released: August 25, 2023

Expiration: August 24, 2024

Shaji K. Kumar
Shaji K. Kumar, MD
Jeffrey P. Sharman
Jeffrey P. Sharman, MD
Eunice S. Wang
Eunice S. Wang, MD
CME/CE Information

Activity

Progress
1
Course Completed

Introduction

In this module, recognized experts in the field discuss key studies in hematologic malignancies presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including Eunice S. Wang, MD, discussing leukemias and myelodysplastic syndromes (MDS); Jeffrey Sharman, MD, discussing lymphomas and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); and Shaji Kumar, MD, discussing multiple myeloma (MM). Please note that the key points discussed in this module are illustrated with thumbnails from capsule summary slidesets from CCO coverage of the ASCO 2023, which are available here.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with hematologic malignancies do you provide care for in a typical month?

What was the primary finding of the interim analysis of the phase III COMMANDS trial with luspatercept vs epoetin alfa for patients with transfusion-dependent lower-risk MDS who are erythropoiesis-stimulating agent (ESA) naive?

A patient with anemia due to low-risk non-del(5q) MDS without ring sideroblasts (RS) has not responded to treatment with epoetin alfa and remains transfusion dependent, requiring approximately 2 units of red blood cell (RBC) transfusion every 2 weeks.

Which of the following investigational agents would you discuss with this patient as a promising therapy to consider based on evidence from a randomized, placebo-controlled phase III trial reported by Zeidan and colleagues?

You are discussing treatment options with a patient who recently presented with relapsed diffuse large B-cell lymphoma (DLBCL) after 2 previous lines of therapy. In your discussion, you would tell the patient that which of the following bispecific antibodies is approved by the FDA and administered by SC injection?

At ASCO 2023, updated results were reported from the phase I/II BRUIN trial of the noncovalent BTK inhibitor pirtobrutinib for patients with mantle cell lymphoma (MCL). In which of the following patient subgroups were response rates of >50% observed?

The CARTITUDE-4 phase III trial evaluated ciltacabtagene autoleucel (cilta-cel) vs pomalidomide/bortezomib/dexamethasone or daratumumab/pomalidomide/dexamethasone (standard of care [SoC]) in patients with lenalidomide-refractory MM after 1-3 prior lines of therapy. In which of the following patient populations was progression-free survival (PFS) benefit demonstrated with cilta-cel compared with SoC?

Which of the following investigational BCMA-targeted CAR T-cell therapies has a manufacturing time of ≤2 days?

BACK | NEXT